

# Anticoagulants: Market Research Report

<https://marketpublishers.com/r/A3E77FDF275EN.html>

Date: January 2019

Pages: 285

Price: US\$ 5,600.00 (Single User License)

ID: A3E77FDF275EN

## Abstracts

This report analyzes the worldwide markets for Anticoagulants in US\$ Million by the following Segments: Oral Anticoagulants, and Injectable Anticoagulants (Unfractionated Heparin, & Low Molecular Weight Heparin).

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024.

Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs. The report profiles 48 companies including many key and niche players such as -

Abbott India Limited

Aspen Holdings

Bayer AG

Boehringer Ingelheim

Bristol-Myers Squibb Company

Mitsubishi Tanabe Pharma Corporation

## Contents

### I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

Oral Anticoagulants

Injectable Anticoagulants

### II. EXECUTIVE SUMMARY

#### 1. GLOBAL MARKET OVERVIEW

Venous ThromboEmbolicism (VTE) – A Prelude

Anticoagulants Market Driven by Novel Oral Anti-coagulants

Sizing the Market

Safety Issues Associated with Erstwhile Market Leaders – Warfarin & Heparins

Anticoagulants – Evolution from Injectables to Oral Drugs

Conventional Oral Drug – Warfarin – Face the Heat

The Newer Breed of NOACs

Comparative Analysis of Warfarin and Novel Oral Anticoagulants

**Table 1.** Global Market for Leading Oral Drugs (2016): Percentage Market Share Breakdown of Value Sales for Eliquis, Xarelto, Pradaxa, and Others (includes corresponding Graph/Chart)

Bevyxxa (Betrixaban) – The Latest Approved NOAC

Aging Population: A Crucial Driver for Anticoagulants Market

**Table 2.** Global Population Statistics for the 60+ Age Group by Region (2017) (includes corresponding Graph/Chart)

**Table 3.** Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in '000s and as a Percentage of Total Population for 2015 & 2050 (includes

corresponding Graph/Chart)

**Table 4.** Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)

**Table 5.** Global Life Expectancy at Birth (Years) by Geographic Region: 1950-2050 (includes corresponding Graph/Chart)

**Table 6.** Life Expectancy for Select Countries in Number of Years: 2016 (includes corresponding Graph/Chart)

Global Menace of Cardiovascular Disease – A Major Growth Factor

**Table 7.** Global Annual Medical Cost of CVD in US\$ Billion (2010-2030) (includes corresponding Graph/Chart)

**Table 8.** Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)

Increasing Prevalence of AF Impacts Growth Prospects

Rising Stroke Statistics – An Opportunity Indicator for Anticoagulants

Increasing Incidence of Knee/Hip Replacement Surgeries Drive Market Growth

**Table 9.** Hip Replacement per 100,000 Population in Select Countries (includes corresponding Graph/Chart)

**Table 10.** Knee Replacement per 100,000 Population in Select Countries (includes corresponding Graph/Chart)

Increasing Healthcare Spending in Emerging Markets

**Table 11.** Healthcare Spending as a Percentage of GDP by Region: 2016 (includes corresponding Graph/Chart)

**Table 12.** Per-Capita Healthcare Expenditure in US\$ for Select Countries/Regions

(2016) (includes corresponding Graph/Chart)

Adverse Effects: A Key Market Deterrent  
Common Adverse Effects of NOAC Therapies  
Increased Bleeding – A Major Concern with Newer Agents  
Novel Oral Drugs: Absence of Antidote & Other Concerns  
US FDA Delays Andexxa (the Xarelto and Eliquis Antidote) Approval  
Reversal Agents for DOACs  
Threat of Generics Looms Large on the Anti-Coagulants Market  
Patent Expiries of Oral Anticoagulants  
Pipeline Analysis  
Tecarfarin (Espero BioPharma)  
List of Ongoing NOAC Studies

## **2. MARKET TRENDS & ISSUES**

NOACs to Emerge as Mainstream Option for VTE Patients  
NICE Guidelines Promote NOAC Usage in Atrial Fibrillation  
NOACs as Alternative/Supplement to Antiplatelet Therapy  
Increase in Heparin Trade Boosts the Market  
Modern Developments Improving Anticoagulation Management  
Researchers Find Significant Correlation between NOAC and Newer Health Risks  
NOAC Underdosing Trend Restrains Universal Acceptance  
Underutilization of Oral Anticoagulants in Atrial Fibrillation  
Generics Prevail in the Traditional Market  
Patent Expiries of Traditional Anticoagulants in the US  
Inadequate Trials Mar Pediatric Anticoagulants Market  
New Advancements Improve Anticoagulation Management  
Growing Demand for Self-Testing  
LMWHs Ease Outpatient Management

## **3. SEGMENT ANALYSIS**

Oral Anticoagulant Agents  
Traditional Oral Anticoagulants  
Warfarin  
Coumadin – The Branded Warfarin  
Advantages and Alternatives  
Side Effects

## Limitations

Novel Oral AntiCoagulants (NOAC)

Approved Indications of Various NOACs by Geographic Region

Approved Anticoagulant Agents in a Nutshell

Pradaxa (Dabigatran Etexilate)

Pradaxa and Warfarin - A Comparative Study

Xarelto (Rivaroxaban)

Xarelto Patent Expiry in Various Regions

Apixaban (Eliquis)

Savaysa (Edoxaban)

Bevyxxa (betrixaban)

Injectable Anticoagulants

Injectable Anticoagulants – An Insight

Heparin – The Backbone of Injectable Anticoagulants

Unfractionated Heparin

Advantages and Alternatives

Limitations

Low Molecular Weight Heparins (LMWH)

Indications

Advantages

A Focus on Select Heparin-based Injectables

Lovenox/Clexane (enoxaparin)

Approved Indications for Lovenox

Advantages and Alternatives

Fragmin (dalteparin sodium)

Approved Indications for Fragmin Use

Fraxiparine (nadroparin)

Innohep (tinzaparin)

Normiflo (ardeparin)

Clivarine (reviparin)

Non-Heparin Anticoagulant Injectables – An Overview

Arixtra (fondaparinux)

Angiomax (bivalirudin)

Advantages

Argatroban/Novastan

Side Effects

## 4. THERAPEUTIC INDICATIONS

Venous/DVT Thrombosis Indications  
Venous Thromboembolism  
Venous Thromboembolism—Causes and Symptoms  
Deep Vein Thrombosis  
Pulmonary Embolism  
Orthopedic (Hip or Knee Replacement) Surgery  
General Surgery  
Cancer  
Arterial Thrombosis Indications  
Arterial Thrombosis  
Acute Coronary Syndromes  
Atrial Fibrillation  
Unstable Angina  
List of Approved Anticoagulants for Unstable Angina  
Myocardial Infarction  
Non ST-Segment Elevation MI  
Percutaneous Transluminal Coronary Angioplasty (PTCA)  
Heparin Induced Thrombocytopenia (HIT) Indications  
Heparin Induced Thrombocytopenia with Thrombosis (HITTS)  
Other Indications  
Hemodialysis

## **5. PRODUCT INTRODUCTIONS/APPROVALS**

Mylan Pharmaceuticals Inc. Agrees to hold off Pradaxa's generic version  
Portola Pharmaceuticals Declares Results of CHMP Oral Explanations for Andexanet Alfa and Betrixaban  
Daiichi Sankyo Introduces Anticoagulant Lixiana OD Tablets  
FDA again Delays Approval of AndexXa  
US FDA Approves Bayer's Xarelto  
Portola Pharmaceuticals Receives U. S FDA Approval for Bevyxxa  
Armethion Receives European Medicines Agency's Support for Studying Tecarfarin prior to MAA Filing  
Armethion Agrees with FDA for Conducting a Study for Tecarfarin Prior to NDA Filing  
Rivaroxaban (Xarelto) Receives Patent Term Extension in US  
Armethion Declares Positive Results of Tecarfarin versus Warfarin  
FDA Approves Pradaxa Antidote Praxbind  
CFDA Approves Bayer's Xarelto  
Raplixa Anticoagulant by MDCO Receives FDA Approval

Teva Launches Argatroban Injection in the US Market  
BMS and Pfizer Announce Phase III Results of Apixaban  
Boehringer Ingelheim Receives Priority Review by FDA for Idarucizumab BLA  
FDA Grants Fast Track Designation to Perosphere's PER977  
FDA Approves Savaysa/Edoxaban

## 6. RECENT INDUSTRY ACTIVITY

Daiichi Sankyo Introduces Anticoagulant Lixiana OD Tablets in Japan  
Bristol-Myers Squibb and Pfizer Presents New Analyses for Eliquis (apixaban) Clinical and Real-World Data  
Espero Pharmaceuticals and Armetheon Plans to Merge  
Portola Pharmaceuticals Signs a Loan Agreement with Pfizer and Bristol-Myers Squibb  
Momenta Pharmaceuticals Presents Data on Necuparanib at the ASCO Annual Meeting  
Reig Jofre Acquires Chiesi España SA a sodium heparin  
Chiesi Acquires Three Hospital Products - Kengreal, Cleviprex and Argatroban for Injection  
Bayer Collaborates with Janssen on Extended Clinical Investigation of Xarelto  
Bayer to Acquire Experimental Anticoagulant from Isis Pharmaceuticals

## 7. FOCUS ON SELECT GLOBAL PLAYERS

Abbott India Limited (India)  
Aspen Holdings (South Africa)  
Bayer AG (Germany)  
Boehringer Ingelheim (Germany)  
Bristol-Myers Squibb Company (USA)  
Mitsubishi Tanabe Pharma Corporation (Japan)  
Pfizer, Inc. (USA)  
Sanofi S. A. (France)  
Teva Pharmaceutical Industries Ltd. (Israel)

## 8. GLOBAL MARKET PERSPECTIVE

**Table 13.** World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding



Graph/Chart)

**Table 14.** World Historic Review for Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 15.** World 14-Year Perspective for Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

**Table 16.** World Recent Past, Current & Future Analysis for Oral Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 17.** World Historic Review for Oral Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 18.** World 14-Year Perspective for Oral Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

**Table 19.** World Recent Past, Current & Future Analysis for Injectable Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 20.** World Historic Review for Injectable Anticoagulants by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)



**Table 21.** World 14-Year Perspective for Injectable Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

**Table 22.** World Recent Past, Current & Future Analysis for Injectable Anticoagulants by Product Segment - Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 23.** World Historic Review for Injectable Anticoagulants by Product Segment - Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 24.** World 14-Year Perspective for Injectable Anticoagulants by Product Segment - Percentage Breakdown of Dollar Sales for Unfractionated Heparin and Low Molecular Weight Heparin Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

**Table 25.** World Recent Past, Current & Future Analysis for Unfractionated Heparin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 26.** World Historic Review for Unfractionated Heparin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 27.** World 14-Year Perspective for Unfractionated Heparin by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

**Table 28.** World Recent Past, Current & Future Analysis for Low Molecular Weight Heparin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed

with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 29.** World Historic Review for Low Molecular Weight Heparin by Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 30.** World 14-Year Perspective for Low Molecular Weight Heparin by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

### III. MARKET

#### 1. THE UNITED STATES

##### A. Market Analysis

##### Key Statistics

US: The Largest Market for Anti-Coagulants

A List of FDA Approved Anticoagulants

Eliquis and Xarelto lead the US NOAC Market

**Table 31.** The US Oral Anti-Coagulants Market by Leading Players (2016): Market Share of Breakdown of Total Prescriptions for Warfarin, Xarelto, Eliquis, Pradaxa, and Savaysa (includes corresponding Graph/Chart)

**Table 32.** The US Oral Anti-Coagulants Market by Leading Players (2016): Market Share of Breakdown of Total Sales for Xarelto, Eliquis, Pradaxa, and Others (includes corresponding Graph/Chart)

AndexXa – Another Reversal Agent for NOAC

Growth Drivers/Trends

Atrial Fibrillation – A Key Risk Factor, Driving the Demand for Anti-Coagulants

Rapidly Ageing Demographics Drive Growth in the Anticoagulants Market

**Table 33.** North American Aging Population by Age Group: 1975-2050 (includes

corresponding Graph/Chart)

Surge in CVD Incidence – Major Growth Factor

**Table 34.** CVD in the US: Cardiovascular Disease Prevalence in Adults by Gender & Age Group (includes corresponding Graph/Chart)

**Table 35.** Leading Causes of CVD Fatalities in the US: Percentage Breakdown of Mortality for Coronary Heart Disease, HBP, Heart Failure, Stroke, and Others (includes corresponding Graph/Chart)

Manufacturers' Patient Assistance Programs Support Increased Sales

US Injectable Anti-Coagulants Market

Decline in Heparin Demand

Extending the Use of Heparin to New Indications

Product Introductions/Approvals

Strategic Corporate Developments

Select Key Players

B. Market Analytics

**Table 36.** The US Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 37.** The US Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 38.** The US 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

## 2. CANADA

## Market Analysis

**Table 39.** Canadian Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 40.** Canadian Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 41.** Canadian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

### 3. JAPAN

#### A. Market Analysis

##### Graying Population Spurs Growth of Anticoagulants

**Table 42.** Japanese Aging Population by Age Group: Year Ending June 1, 2017 (includes corresponding Graph/Chart)

#### Product Launches

#### Select Key Players

#### B. Market Analytics

**Table 43.** Japanese Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 44.** Japanese Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 45.** Japanese 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

## 4. EUROPE

### A. Market Analysis

Europe: A Major Anti-Coagulant Market

Increasing Aging Population Boosts Demand

**Table 46.** Aged Population in the EU (2016): Population Over 65+ Years as % of Total Population (includes corresponding Graph/Chart)

New Drugs Drive Use of Oral Anticoagulants in Atrial Fibrillation Patients

### B. Market Analytics

**Table 47.** European Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 48.** European Historic Review for Anticoagulants by Geographic Region/Country - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 49.** European 14-Year Perspective for Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

**Table 50.** European Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 51.** European Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 52.** European 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

#### **4A. FRANCE**

A. Market Analysis

Sanofi S. A. – A Key Player

B. Market Analytics

**Table 53.** French Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 54.** French Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 55.** French 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)



## 4B. GERMANY

### A. Market Analysis

Strategic Corporate Developments

Focus on Select Key Players

### B. Market Analytics

**Table 56.** German Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 57.** German Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 58.** German 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

## 4C. ITALY

### Market Analysis

**Table 59.** Italian Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 60.** Italian Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)



**Table 61.** Italian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

#### **4D. THE UNITED KINGDOM**

##### A. Market Analysis

Stroke Statistics – Opportunity Indicator for Anticoagulants

NICE Guidelines Promote NOAC Usage

##### B. Market Analytics

**Table 62.** The UK Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 63.** The UK Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 64.** The UK 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

#### **4E. SPAIN**

##### A. Market Analysis

Strategic Corporate Development

##### B. Market Analytics

**Table 65.** Spanish Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with

Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 66.** Spanish Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 67.** Spanish 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

#### **4F. RUSSIA**

Market Analysis

**Table 68.** Russian Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 69.** Russian Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 70.** Russian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

#### **4G. REST OF EUROPE**

Market Analysis

**Table 71.** Rest of Europe Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 72.** Rest of Europe Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 73.** Rest of Europe 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

## 5. ASIA-PACIFIC

### A. Market Analysis

Highly Populated Asian Countries Offer Significant Growth Opportunities

**Table 74.** Over 65 Years Individuals as % of the Total Population in Select Asian Countries: 2016 (includes corresponding Graph/Chart)

### B. Market Analytics

**Table 75.** Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 76.** Asia-Pacific Historic Review for Anticoagulants by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 77.** Asia-Pacific 14-Year Perspective for Anticoagulants by Geographic

Region/Country - Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

**Table 78.** Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 79.** Asia-Pacific Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 80.** Asia-Pacific 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

## 5A. CHINA

### A. Market Analysis

Favorable Reimbursement for NOACs

LMWH – The leading Heparin Segment

Product Launch

### B. Market Analytics

**Table 81.** Chinese Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 82.** Chinese Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 83.** Chinese 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

## **5B. INDIA**

### A. Market Analysis

Abbott India Limited – A Key Player

### B. Market Analytics

**Table 84.** Indian Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 85.** Indian Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 86.** Indian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

## **5C. REST OF ASIA-PACIFIC**

### Market Analysis

**Table 87.** Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 88.** Rest of Asia-Pacific Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 89.** Rest of Asia-Pacific 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

## 6. LATIN AMERICA

### Market Analysis

**Table 90.** Latin American Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 91.** Latin American Historic Review for Anticoagulants by Geographic Region/Country - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 92.** Latin American 14-Year Perspective for Anticoagulants by Geographic Region/Country - Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin America Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

**Table 93.** Latin American Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 94.** Latin American Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)



**Table 95.** Latin American 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

## **6A. BRAZIL**

Market Analysis

**Table 96.** Brazilian Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 97.** Brazilian Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 98.** Brazilian 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

## **6B. REST OF LATIN AMERICA**

Market Analysis

**Table 99.** Rest of Latin American Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 100.** Rest of Latin American Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low



Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 101.** Rest of Latin American 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

## 7. REST OF WORLD

A. Market Analysis

Select Key Players

B. Market Analytics

**Table 102.** Rest of World Recent Past, Current & Future Analysis for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

**Table 103.** Rest of World Historic Review for Anticoagulants by Product Type - Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

**Table 104.** Rest of World 14-Year Perspective for Anticoagulants by Product Type - Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

## IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 48 (including Divisions/Subsidiaries - 58)

The United States (23)

Japan (3)

Europe (30)

France (1)

Germany (4)

The United Kingdom (4)  
Spain (1)  
Rest of Europe (5)  
Asia-Pacific (Excluding Japan) (15)  
Africa (2)

## I would like to order

Product name: Anticoagulants: Market Research Report

Product link: <https://marketpublishers.com/r/A3E77FDF275EN.html>

Price: US\$ 5,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A3E77FDF275EN.html>